Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients

NCT04364737 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04364737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
April 17, 2020
Completion date
December 12, 2022
Enrollment
941 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, coronavirus infection, covid-19